The way cancer is diagnosed and treated has undergone a fundamental transformation over the past two decades. Rather than categorizing tumors strictly by organ of origin and anatomical stage, modern precision oncology looks directly at tumors at the molecular level. A tumor profiling test is the diagnostic tool that makes this molecular evaluation possible, moving genomic insights from a clinical research tool into routine oncology practice.
What Tumor Profiling Is
Tumor profiling analyzes the genetic and molecular characteristics of cancer cells to identify specific mutations, gene expression patterns, and structural variants. As cancer cells grow, they accumulate somatic mutations—acquired genetic alterations that are present exclusively within tumor cells and absent in healthy tissues.
- Distinct tumors arising in the same organ often harbor vastly different molecular profiles:
- Targeted Sensitivity: A lung adenocarcinoma with an EGFR exon 19 deletion responds directly to EGFR tyrosine kinase inhibitors (TKIs) like osimertinib.
- Non-Responder Profile: A lung adenocarcinoma of identical stage without an EGFR mutation will not benefit from EGFR-targeted TKIs.
Without comprehensive tumor profiling, patients with identical histological diagnoses receive uniform treatments despite having distinct underlying molecular drivers.
What a Tumor Profiling Test Detects
Advanced Next-Generation Sequencing (NGS) panels evaluate several major categories of genomic alterations:
- Somatic Point Mutations: Single Nucleotide Variants (SNVs) and small Insertions/Deletions (Indels) in critical cancer driver genes (e.g., KRAS, BRAF, PIK3CA).
- Copy Number Variants (CNVs): Gene amplifications (e.g., HER2/ERBB2 amplification) or gene deletions (e.g., PTEN loss) that alter cellular growth signals.
- Gene Fusions / Translocations: Chimeric genes resulting from structural rearrangements, such as ALK, ROS1, RET, or NTRK fusions commonly found in non-small cell lung cancer (NSCLC) and rare solid tumors.
- Tumor Mutational Burden (TMB) & Microsatellite Instability (MSI): Biomarkers that measure overall genomic instability to predict patient response to immune checkpoint inhibitors.
The tumor profiling test available through Medgenome’s TumourTrack Advance platform provides comprehensive somatic mutation profiling across a clinically relevant gene panel, with reporting structured to support oncologist decision-making.
How Profiling Guides Treatment Decisions
When a profiling result identifies a targetable mutation, the clinical implication is specific. An EGFR mutation in a lung cancer patient means EGFR-targeted therapy is an appropriate option. A BRCA mutation in an ovarian cancer patient means PARP inhibitor therapy has a biological rationale. An ALK fusion in a lung cancer patient identifies a class of ALK inhibitor drugs that produce high response rates in that specific molecular context. These are not general associations. They are the basis of treatment selection in targeted oncology.
When profiling does not identify a targetable mutation, the result also has value. It rules out treatment approaches that would not be effective and may identify a high tumor mutational burden that supports immunotherapy as an alternative. Knowing what a tumor does not have is useful clinical information alongside knowing what it does.
Liquid Biopsy in Tumor Profiling
When obtaining a tissue sample is not feasible or carries significant risk, tumor DNA testing through liquid biopsy offers an alternative. The tumor sheds DNA into the bloodstream as it grows, and this circulating tumor DNA carries the same mutations present in the cancer cells. A blood draw rather than a tissue biopsy makes profiling accessible in situations where the tumor cannot be biopsied safely, and in monitoring settings where tracking molecular changes over time requires repeated sampling.
The tumor DNA testing capability within TumourTrack Advance covers both tissue-based and liquid biopsy profiling, with reporting that connects molecular findings to clinical actionability in a format designed for oncology treatment planning.
Read More: Why Admission to an AI Course is Becoming a New Career Launchpad?